STOCK TITAN

Director Kevin Donahue updates 685,000-share stake in Mainz Biomed (MYNZ)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A

Rhea-AI Filing Summary

Mainz Biomed N.V. insider ownership has been updated in an amended Form 3. Director Kevin Donahue reports beneficial ownership of 685,000 shares of common stock, held directly. This amendment corrects a prior filing made on 01/16/2026 and is an administrative update to accurately reflect his reported holdings.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Donahue Kevin Michael

(Last) (First) (Middle)
2502 KIRBY STREET

(Street)
DALLAS TX 75204

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/17/2025
3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
01/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 685,000 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Correction to Form 3 Filing made on 1/16/2026.
Kevin Donahue 01/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the amended Form 3/A for MYNZ report?

The amended Form 3/A reports that director Kevin Donahue beneficially owns 685,000 shares of Mainz Biomed N.V. common stock, held directly, correcting a prior filing.

Who is the reporting person in this Mainz Biomed (MYNZ) Form 3/A?

The reporting person is Kevin Donahue, who is identified as a director of Mainz Biomed N.V.

How many MYNZ shares does Kevin Donahue report owning?

Kevin Donahue reports beneficial ownership of 685,000 shares of Mainz Biomed N.V. common stock, shown as direct (D) ownership.

Is Kevin Donahue’s ownership in MYNZ reported as direct or indirect?

The 685,000 Mainz Biomed N.V. shares are reported as direct (D) ownership, with no indirect ownership nature indicated.

What correction is noted in the MYNZ Form 3/A remarks?

The remarks state: “Correction to Filing made on 1/16/2026.” This indicates the current Form 3/A amends that earlier submission.

Does this MYNZ Form 3/A show any derivative securities?

The table for derivative securities is included but shows no derivative securities listed as beneficially owned.
Mainz Biomed NV

NASDAQ:MYNZ

MYNZ Rankings

MYNZ Latest News

MYNZ Latest SEC Filings

MYNZ Stock Data

10.69M
8.99M
1.63%
8.43%
2.35%
Diagnostics & Research
Healthcare
Link
Germany
Mainz